Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients
about
Interleukin 12: still a promising candidate for tumor immunotherapy?Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant MelanomaClinical validation of IFNγ/IL-10 and IFNγ/IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans.Administration of recombinant rhesus interleukin-12 during acute simian immunodeficiency virus (SIV) infection leads to decreased viral loads associated with prolonged survival in SIVmac251-infected rhesus macaques.IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy.Pluripotent and Multipotent Stem Cells Display Distinct Hypoxic miRNA Expression ProfilesPhase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma.Networking the host immune response in Plasmodium vivax malaria.Immunotherapy of cancer by IL-12-based cytokine combinationsOncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-α-co-producing T cell-mediated antitumor immunity.Interleukins and cancer immunotherapy.Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27.Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.Lentiviral vectors in cancer immunotherapy.Gene therapy approaches against cancer using in vivo and ex vivo gene transfer of interleukin-12.Central role of IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunityBiodegradable polymer-based interleukin-12 gene delivery: role of induced cytokines, tumor infiltrating cells and nitric oxide in anti-tumor activity.Q56898607Cytokine production and T-cell activation by macrophage-dendritic cells generated for therapeutic useTurn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
P2860
Q26861559-076D5505-8A2B-4235-A66C-ACC040F4E9C9Q33423772-6A6ACACA-C485-4327-85E5-DB5E0A0D503CQ34271609-312B5996-D648-4136-B6FA-6F768A0362FFQ34331118-3432201C-8C21-4519-827C-9E66A8E6A795Q34798580-C7E39B1F-9170-45E2-A6C4-3B2CC4A9F710Q35582297-5012FBF2-1560-407C-9106-B18B76F65A58Q36175145-80ADD420-BE74-4624-9E8B-324FF79907C3Q36447950-B495FA07-8A6B-4FFD-8BDA-A6BDC91EE6FDQ36686824-B63F7D46-2C19-4990-B832-14799D08CB15Q36724827-7057E3BC-799E-41A7-BE69-99D4AC3645F8Q36981396-25066CF2-C897-4778-A212-38108E6BACA0Q37773302-F50A01DD-257A-440C-8F10-9ABF38BAEE4FQ37795583-EB0E8A83-CE31-4840-A429-BB58F67E515CQ37830361-96FE379F-5E58-42C8-BC92-7AAEBBF4A359Q38389312-AD7120E7-6E68-4D18-92A8-D60F66268269Q38703318-DA9CD53A-DBCB-4913-9A94-37B7AC9C1CE4Q42130331-67502F1F-F57D-4EDC-BA02-925168706D96Q44078795-6DCB8645-D7E4-4D0E-A79E-62252029E3DAQ56898607-604EF3D4-2731-44C1-B446-672A63AEE5C7Q56966277-F39D864B-4F5F-421F-9754-D2157EDA29F8Q58780996-9F775C4A-3C3B-4E3E-B1E0-EE76E1D71B95
P2860
Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients
description
im Januar 2000 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 January 2000
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2000
@uk
name
Cytokines and soluble cytokine ...... inistration in cancer patients
@en
Cytokines and soluble cytokine ...... inistration in cancer patients
@nl
type
label
Cytokines and soluble cytokine ...... inistration in cancer patients
@en
Cytokines and soluble cytokine ...... inistration in cancer patients
@nl
prefLabel
Cytokines and soluble cytokine ...... inistration in cancer patients
@en
Cytokines and soluble cytokine ...... inistration in cancer patients
@nl
P2093
P2860
P1476
Cytokines and soluble cytokine ...... inistration in cancer patients
@en
P2093
B Escudier
N Haicheur
P H De Mulder
P Pouillart
P2860
P356
10.1046/J.1365-2249.2000.01112.X
P407
P577
2000-01-01T00:00:00Z